On March 6, 2024 Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, reported that it will present data from its differentiated immuno-oncology preclinical and clinical pipeline, in two poster presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) annual meeting on April 5-11, 2024, in San Diego, California (Press release, Compugen, MAR 6, 2024, View Source [SID1234640880]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is exciting that the progress we have made to potentially address immunotherapy resistance from diverse angles will be reflected at AACR (Free AACR Whitepaper) this year," said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. "While PVRIG and TIGIT are novel targets discovered with our computational discovery platform, more recently, we have also discovered a unique and differentiated way to target a known biological pathway, the IL-18 binding protein pathway."
Eran Ophir, Ph.D., Chief Scientific Officer at Compugen, added, "At ACCR we will present data supporting the unique biology of PVRIG suggesting its role in sensitizing tumors to other immune checkpoints TIGIT and PD-(L)1. In addition, in a second presentation we will present data supporting the therapeutic potential of our high affinity, potential first-in-class, anti-IL-18 binding protein antibody, COM503, showing its activity is localized to the tumor microenvironment with the potential advantage of a wider therapeutic window than systemically delivered cytokines."
Poster details:
Session Date and Time: Tuesday, April 9, 2024, 9:00 AM – 12:30 PM PST
Session Category: Immunology
Session Title: Immune Modulation with Cytokines
Poster Title: Unleashing natural IL-18 activity using an anti-IL-18BP blocker antibody induces potent immune stimulation and anti-tumor effects
Published Abstract Number: 4072
Session Date and Time: Wednesday, April 10, 2024, 9:00 AM – 12:30 PM PST
Session Category: Clinical Research
Session Title: Immune Checkpoint Inhibitor Therapy
Poster Title: PVRIG is uniquely expressed in tumor dendritic cells-rich niches on stem-like memory T cells and its blockade may induce immune infiltration and activation in non-inflamed tumor
Published Abstract Number: 7533
The abstracts are available on Compugen’s website at www.cgen.com. The data will be published in the online Proceedings supplement to the AACR (Free AACR Whitepaper) journal Cancer Research prior to the meeting on Friday, March 22, 2024.